OUR TEAM2018-08-30T13:47:43+00:00

OUR TEAM

Gentronix Ltd. comprises a team of people who are passionate about the science of toxicology. Combined, we have decades of experience within predictive toxicology space and the SME environment and together we are committed to delivering the highest quality science, in an effective and efficient manner.

A WEALTH OF EXPERIENCE

JOHN NICHOLSON
JOHN NICHOLSONChairman
As Chairman of Gentronix, John provides guidance to the Board of Directors on our strategic aims. He has a wealth of experience of managing and growing both SMEs and £15m – £200m global businesses, most recently as CEO and Chairman roles for VC-backed development stage businesses. John has experience of IPO, M&A, restructuring and divestment; as well as raising finance from multiple sources for SMEs. John also sits as NED of the North West Business Fund.
MATT TATE
MATT TATEManaging Director
Matt has been with the business for over 12 years. Initially working on the development of our screening assays and earning a PhD in genetic toxicology, Matt transitioned to the commercial side of the business, working globally with clients to implement the most appropriate testing strategies for their needs. He now leads the business, developing our overall strategy and delivering our plan to build an expert predictive toxicology CRO, whilst remaining passionate about toxicology and engaging with our clients to meet their challenges.
NICK BILLINTON
NICK BILLINTONOperations Director
Nick is one of the company’s originating scientists, initially as a PhD student in the founding lab. Post-PhD, Nick led the research efforts to develop the GreenScreen® HC & BlueScreen™ HC technologies, and then the transition of the business to a CRO. Providing project management and scientific leadership, Nick implemented GLP compliance in the organisation. As Operations Director, Nick continues to ensure our commitment to expert delivery of high quality science is maintained.
PAUL RAWLINSON
PAUL RAWLINSONLead Toxicologist
Paul recently joined Gentronix after working as a general and genetic toxicologist at a major agrochemical R&D company for 11 years. Prior to that he had experience in the cosmetics industry and in pharmaceutical literature services. Paul’s skills and experience includes designing testing strategies, data interpretation, product development and regulatory product safety advocacy.

OUR VALUES

OUR VALUES

Our business origins are in the delivery of innovative screening products for toxicological hazard; challenging the established approach with scientific rigour. Building on our experiences of developing market leading predictive toxicology assays, we have extended our expertise to the regulatory tests for genetic toxicology and recently skin sensitisation.

We make a commitment to our clients to perform toxicology studies of the highest scientific quality; not merely to produce data, but to deliver the most appropriate data endpoints, using the right assay tools, guided by scientific engagement and experience. Furthermore, we are committed to helping our clients understand and interpret their results, supporting navigation of regulatory landscapes and management of adverse toxicology findings.

This is guided by our core values, which we apply to all the studies we perform:

  • Excellence; we strive to deliver the highest quality service using the most appropriate scientific tools.

  • Effectiveness; we aim to deliver high quality results when you need them.

  • Efficiency; we optimise our approach to deliver maximum data from minimum material.

  • Engagement; we engage scientifically to support study design through to data interpretation and management.

Our business origins are in the delivery of innovative screening products for toxicological hazard; challenging the established approach with scientific rigour. Building on our experiences of developing market leading predictive toxicology assays, we have extended our expertise to the regulatory tests for genetic toxicology and recently skin sensitisation.

We make a commitment to our clients to perform toxicology studies of the highest scientific quality; not merely to produce data, but to deliver the most appropriate data endpoints, using the right assay tools, guided by scientific engagement and experience. Furthermore, we are committed to helping our clients understand and interpret their results, supporting navigation of regulatory landscapes and management of adverse toxicology findings.

This is guided by our core values, which we apply to all the studies we perform:

  • Excellence; we strive to deliver the highest quality service using the most appropriate scientific tools.

  • Effectiveness; we aim to deliver high quality results when you need them.

  • Efficiency; we optimise our approach to deliver maximum data from minimum material.

  • Engagement; we engage scientifically to support study design through to data interpretation and management.

SCREENING & SAFETY

Predictive Genotoxicity Screening

We offer a broad range of rapid turnaround screens, focussed on low test item usage, to detect and contextualise genotoxic liability early in development.

Find out more

Regulatory Genotoxicity Studies

We offer GLP Ames, mouse lymphoma and in vitro micronucleus studies that allow clients to demonstrate chemical safety and address their regulatory requirements.

Find out more

Skin Sensitisation

Providing DPRA, KeratinoSensTM and h-CLAT assays, we enable several key events of the skin sensitisation adverse outcome pathway to be assessed.

Find out more

Flow Cytometry Services

Working we our clients, we utilise our flow cytometry experience and expertise to deliver a diverse range of endpoints.

Find out more

Predictive Toxicology, Expertly Delivered

GET IN TOUCH